NanoViricides, Inc. (NASDAQ:NNVC)

PRESS RELEASE

published on 07/30/2025 at 14:30, 10 months 30 days ago

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
NanoViricides introduces drug candidate NV-387 as a potential treatment for Measles outbreak. The drug has shown safety and effectiveness in animal studies and Phase I trial, aiming to combat the global epidemic

NanoViricides NV-387 Antiviral Vaccination Measles
BRIEF

published on 07/23/2025 at 14:35, 11 months 6 days ago

NanoViricides explore le potentiel de l'antiviral à large spectre NV-387

NV-387 Antiviral À Large Spectre Approbation Réglementaire Préparation Aux Pandémies Statut De Médicament Orphelin
BRIEF

published on 07/23/2025 at 14:35, 11 months 6 days ago

NanoViricides Explores Potential of Broad-Spectrum Antiviral NV-387

NV-387 Regulatory Approval Broad-spectrum Antiviral Pandemic Preparedness Orphan Drug Status
PRESS RELEASE

published on 07/23/2025 at 14:30, 11 months 6 days ago

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value
NanoViricides, Inc. highlights the strong effectiveness of its broad-spectrum antiviral drug NV-387 against various viruses. Expected to drive significant valuation and market share, leading to rapid regulatory approvals and early revenues

NanoViricides NV-387 Antiviral Drug Broad-spectrum Pandemic Preparedness
BRIEF

published on 07/21/2025 at 12:35, 11 months 8 days ago

NanoViricides Develops Promising Measles Antiviral

NanoViricides NV-387 Antiviral Drug Animal Study Measles Treatment
BRIEF

published on 07/21/2025 at 12:35, 11 months 8 days ago

NanoViricides développe un antiviral prometteur contre la rougeole

NanoViricides NV-387 Médicament Antiviral Étude Animale Traitement De La Rougeole
PRESS RELEASE

published on 07/21/2025 at 12:30, 11 months 8 days ago

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides
NanoViricides, Inc., a leading global pioneer in broad-spectrum antivirals, achieves significant success in developing a drug against Measles with NV-387. The drug shows strong antiviral effectiveness in recent studies

NanoViricides NV-387 Clinical Stage Broad-spectrum Antivirals Measles
BRIEF

published on 07/16/2025 at 14:35, 11 months 13 days ago

NanoViricides Advances MPox Treatment Amid WHO Emergency Extension

NV-387 Clinical Trials MPox Epidemic WHO Emergency Antiviral Innovation
BRIEF

published on 07/16/2025 at 14:35, 11 months 13 days ago

NanoViricides fait progresser le traitement MPox dans le cadre de la prolongation de l'autorisation d'urgence de l'OMS

NV-387 Essais Cliniques Épidémie De MPox Urgence De L'OMS Innovation Antivirale
PRESS RELEASE

published on 07/16/2025 at 14:30, 11 months 13 days ago

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
NanoViricides, Inc. comments on WHO's extension of the MPox Public Health Emergency of International Concern and highlights the development of NV-387, a potential broad-spectrum antiviral for MPOX treatment

NanoViricides NV-387 Clinical Trial Mpox Antiviral

Published on 06/30/2026 at 09:01, 3 hours 16 minutes ago

Apex Mobilizes Drill Rig and Commences 2026 Exploration Program at the Cap Critical Minerals Project
Published on 06/30/2026 at 08:05, 4 hours 12 minutes ago

Notice of Annual and Special Meeting of Shareholders
Published on 06/30/2026 at 08:00, 4 hours 17 minutes ago

Exercise of Restricted Share Units
Published on 06/30/2026 at 05:30, 6 hours 47 minutes ago

Nano One Renews At-The-Market Equity Program
Published on 06/30/2026 at 02:00, 10 hours 17 minutes ago

MedMira Reports Third Quarter Results FY2026

View all ACCESSWIRE

Published on 06/30/2026 at 11:37, 40 minutes ago

Drägerwerk AG & Co. KGaA: Notification pursuant to Art. 5 (1) of the Regulation (EU) No 596/2014 and Art. 2 (1) of the Delegated Regulation (EU) 2016/1052 of the Commission
Published on 06/30/2026 at 11:15, 1 hour 2 minutes ago

Greenworks renforce sa localisation en Europe et fait de l’outillage électrique un pilier de sa stratégie mondiale
Published on 06/30/2026 at 11:15, 1 hour 2 minutes ago

Greenworks Deepens Its Localisation Strategy in Europe, Building a New Pillar for Global Growth
Published on 06/30/2026 at 11:05, 1 hour 12 minutes ago

Rockwell Automation Announces German-Language Season of ROKStudios Featuring OEM Lifecycle Perspectives
Published on 06/30/2026 at 11:00, 1 hour 17 minutes ago

Shelly Group Sees Growing Importance of Intelligent Building Automation Amid Increasing Summer Heatwaves

View all EQS

Published on 06/30/2026 at 07:30, 4 hours 47 minutes ago

Gimv sells its stake in AlpenBlu Clinics (formerly Les Psy Réunis), a Swiss provider of outpatient mental healthcare, to Impact Healthcare.
Published on 06/30/2026 at 07:30, 4 hours 47 minutes ago

Gimv cède sa participation dans AlpenBlu Clinics (précédemment Les Psy Réunis), acteur suisse des soins ambulatoires en santé mentale, à Impact Healthcare
Published on 06/30/2026 at 07:30, 4 hours 47 minutes ago

Acquisition of Harwanne Capital Management
Published on 06/30/2026 at 07:30, 4 hours 47 minutes ago

Acquisition de Harwanne Capital Management
Published on 06/30/2026 at 07:00, 5 hours 17 minutes ago

bioMérieux submits 510(k) to U.S. FDA for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens

View all LES ECHOS COMFI WIRE

News